Catalent made a series of deals early this decade to build up its presence in Gosselies. Now, it's planning to wind down cell ...

Arcutis Biotherapeutics and Kowa Pharmaceuticals are cutting ties on their U.S. marketing partnership around Arcutis’ Zoryve ...

With the FDA tightening its guidance around the production of nonbacterial beta-lactam drugs, Swedish CDMO Recipharm is ...

With Enhertu and Datroway, Daiichi Sankyo has made itself a top-tier player in antibody-drug conjugates. | With Enhertu and Datroway, Daiichi Sankyo has made itself a top-tier player in antibody-drug ...

Plotting a challenge to Regeneron’s blockbuster Eylea, Ocular Therapeutix has hired “a key architect” of its rival’s launch ...

The new chairman of the CDC's Advisory Committee on Immunization Practices, Kirk Milhoan, M.D., Ph.D., recently took to the ...

With just a few months to go before Eli Lilly expects to launch its own oral GLP-1 obesity drug, Novo Nordisk is making the ...

GLP-1 giant Eli Lilly has once again taken to the medium of short film to deliver an important message about obesity. | GLP-1 ...

ST Pharm has struck a deal with an undisclosed U.S.-based biotech to produce active pharmaceutical ingredients (APIs) for an ...

In 2025's third quarter, multiple large vaccine developers, including Pfizer and GSK, saw vaccine sales tick up globally ...

Amid a viral social media trend glorifying the halcyon days of 2016, Novo Nordisk has gone back an extra decade to find ...

Hours before Johnson & Johnson revealed strong financial results for 2025 and rosy expect | In Johnson & Johnson's ...